Alumis (ALMS) Projected to Post Earnings on Tuesday

Key Points

• Alumis is set to release its Q2 2025 earnings on August 12th, with expected earnings of ($1.11) per share and revenue of $1.80 million.
• The stock is currently trading at $4.09 and has a 50-day moving average of $3.45, showing a significant range of $2.76 to $13.11 over the past year.
• Analysts have mixed opinions on Alumis, with several recommending a "buy" rating, while target prices vary between $14.00 and $25.00.

Alumis (NASDAQ:ALMS - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Alumis to post earnings of ($1.11) per share and revenue of $1.80 million for the quarter.

Alumis (NASDAQ:ALMS - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.82) EPS for the quarter, missing analysts' consensus estimates of ($1.47) by ($0.35). On average, analysts expect Alumis to post $-9 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Alumis Trading Down 0.7%

ALMS stock traded down $0.03 during midday trading on Friday, hitting $4.30. 718,358 shares of the company traded hands, compared to its average volume of 690,319. Alumis has a twelve month low of $2.76 and a twelve month high of $13.11. The business has a 50 day simple moving average of $3.48 and a 200-day simple moving average of $4.75.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ALMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Alumis by 64.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company's stock worth $77,000 after purchasing an additional 4,926 shares during the period. Rhumbline Advisers grew its position in shares of Alumis by 21.7% during the first quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock valued at $102,000 after purchasing an additional 2,949 shares in the last quarter. Jane Street Group LLC purchased a new position in Alumis in the first quarter worth about $111,000. Goldman Sachs Group Inc. grew its position in Alumis by 24.0% in the first quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company's stock worth $378,000 after acquiring an additional 11,949 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Alumis by 163.2% during the second quarter. Geode Capital Management LLC now owns 1,167,832 shares of the company's stock valued at $3,504,000 after buying an additional 724,133 shares during the period.

Wall Street Analysts Forecast Growth

ALMS has been the subject of a number of research reports. HC Wainwright reiterated a "buy" rating and issued a $14.00 price objective on shares of Alumis in a research report on Friday, July 25th. Wells Fargo & Company began coverage on Alumis in a report on Friday, July 25th. They set an "overweight" rating and a $17.00 target price on the stock. Oppenheimer reduced their target price on Alumis from $26.00 to $25.00 and set an "outperform" rating on the stock in a report on Thursday, May 15th. Finally, Guggenheim upgraded Alumis to a "buy" rating and set a $18.00 target price on the stock in a report on Tuesday, June 10th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Alumis currently has a consensus rating of "Buy" and a consensus target price of $19.80.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.